Want to stay updated on the latest news?
Create a Reader Account today to follow the industries and companies that interest you, and customize your news dashboard. SIGN INTO READER ACCOUNT CREATE READER ACCOUNT
Immunofluorescence Assay (IFA) Market Size to Reach USD 4.01 Billion in 2028; Growing application of IFA in research and clinical diagnostics is also expected to boost demand for kits and drive revenue growth, Says Reports and Data
June 02, 2021 14:00 ET
|
Reports and Data
New York, June 02, 2021 (GLOBE NEWSWIRE) -- Growing prevalence of cancer, rapid advancements in medical and clinical infrastructure, increasing demand for quick and efficient assays, and progressing...
Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting
February 22, 2021 08:30 ET
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells
January 04, 2021 08:00 ET
|
Pandion Therapeutics, Inc.
-Phase 1a trial achieved primary objective of safety and tolerability-PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in...
Pandion Therapeutics Appoints Katina Dorton to its Board of Directors
December 03, 2020 08:00 ET
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
November 16, 2020 16:01 ET
|
Pandion Therapeutics, Inc.
- Enrollment and dosing complete in Phase 1a clinical trial of PT101; top-line results expected early 2021- PT627 systemic PD-1 agonist development candidate nominated; IND-enabling studies expected...
Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020
October 28, 2020 08:00 ET
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics to Participate in Panel Discussion at Stifel 2020 Immunology & Inflammation Virtual Summit
September 24, 2020 08:00 ET
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Biologics Market To Reach USD 625.6 Million By 2026 | Reports And Data
October 10, 2019 12:54 ET
|
Reports and Data
New York, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Rise in prevalence of target chronic diseases like cancer, increase in unhealthy lifestyle habits, mergers and acquisitions by major companies, product...
Global Injectable Drug delivery Market To Reach USD 1,085.80 Billion By 2026 | Reports And Data
May 08, 2019 10:59 ET
|
Reports And Data
Increase in number of chronic diseases coupled with technological advancements globally, are the major factors influencing market growth. Market Size – USD 457.82 billion in 2018, Market Growth -...
Minor League Baseball and Lupus Foundation of America Partner to Raise Awareness of Lupus Among U.S. Hispanic/Latinx Fans
December 11, 2018 14:00 ET
|
Minor League Baseball
LAS VEGAS, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Minor League Baseball™ (MiLB™) today announced a partnership with the Lupus Foundation of America (LFA) to become an Official Partner of MiLB Copa de la...